… versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - thelancet.com
… Platinum-based chemotherapy plus cetuximab in head and neck cancer. … versus cetuximab
with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck

[HTML][HTML] Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

O Leblanc, S Vacher, C Lecerf, E Jeannot… - Cancer Biology & …, 2020 - ncbi.nlm.nih.gov
… Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab
[a … While biomarkers of resistance to cetuximab have been identified in metastatic colorectal …

Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance

E Muraro, G Fanetti, V Lupato, V Giacomarra… - Critical Reviews in …, 2021 - Elsevier
… Currently, cetuximab associated with radiotherapy is limited to the … cetuximab efficacy in
this cancer setting are still lacking. This review focuses on the mechanisms of action of cetuximab

[HTML][HTML] … with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety …

Y Guo, Y Luo, Q Zhang, X Huang, Z Li, L Shen… - … Journal of Cancer, 2021 - Elsevier
… new cases of head and neck cancers worldwide, with … percent of head and neck cancers are
squamous cell carcinoma (… {5-FU}] plus cetuximab followed by cetuximab maintenance until …

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised …

AG Sacco, R Chen, FP Worden, DJL Wong… - The Lancet …, 2021 - thelancet.com
… Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR … or metastatic head and neck squamous
cell carcinoma (HNSCC). … or metastatic squamous cell carcinoma of the head and neck

Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes

JC Park, J Durbeck, JR Clark, DL Faden - Oral Oncology, 2020 - Elsevier
… sequence of cetuximab and ICI in R/M HNSCC may affect clinical outcomes. Cetuximab
prior to ICI was associated with worse outcomes while the efficacy of cetuximab may be …

[HTML][HTML] Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: a meta-analysis

WH Tang, W Sun, GX Long - Medicine, 2020 - journals.lww.com
… Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT)
improves outcomes in locally advanced head and neck squamous cell carcinoma (…

Cetuximab-based vs carboplatin-based chemoradiotherapy for patients with head and neck cancer

L Sun, D Candelieri-Surette… - … –Head & Neck …, 2022 - jamanetwork.com
head and neck squamous cell carcinoma who are ineligible to receive treatment with cisplatin,
should cetuximab… with nonmetastatic head and neck squamous cell carcinoma treated …

… efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic …

M Mei, YH Chen, T Meng, LH Qu… - … in medical oncology, 2020 - journals.sagepub.com
Cetuximab (CTX) has been approved to be administered concurrently with radiotherapy (RT)
to treat locally advanced head and neck squamous cell carcinoma (HNSCC). The aim of …

… plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for …

JC Ham, E van Meerten, WE Fiets, LV Beerepoot… - Head & …, 2020 - Wiley Online Library
Head and neck cancer is the seventh most common cancer … advanced squamous cell
carcinoma of the head and neck (… this study was initiated was cetuximab added to platinum/5FU (…